ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings)
Key Points
- Rocket Lab stock has dropped nearly 45% from its May peak, yet the company just completed a record-fast Space Force launch and on-orbit inspection mission for VICTUS HAZE.
- Morgan Stanley reiterated an Overweight rating and raised its bull-case target to $293, framing the $8 billion Iridium Communications acquisition as evidence Rocket Lab is becoming a smaller SpaceX.
- Bulls are defending the roughly $76 200-day moving average as support, with the August 6 earnings report expected to clarify Neutron's timeline, Iridium integration, and backlog trends.
- Special Report: Four ways your 401(k) may be quietly working against you (From SmartAsset)
Rocket Lab (NASDAQ: RKLB) has been through a punishing stretch, to say the least. After peaking near $151 in May, the stock has fallen almost 45% from its record highs, closing at $82.55 on Thursday, July 10.
The post-SpaceX (NASDAQ: SPCX) IPO rotation out of space stocks, a broader risk-off tape, and heavy insider selling have all weighed on the name. But beneath the ugly chart, the past two weeks have delivered some significant bullish fundamental developments. For long-term investors, the disconnect between price action and recent developments might be hard to ignore and could even signal a potential entry point.
He bet half his $9 billion on ONE stock (Ad)
One of the most successful fund managers of the past 50 years put more than half of his $9 billion portfolio - roughly $4.5 billion - into a single little-known company. Then his firm bought more shares for 61 straight trading days.
The former CEO of Google followed with a nine-figure partnership. The White House invoked emergency powers to protect what this company controls. A July 13th deadline could trigger a flood of institutional buying. Whitney Tilson, who called Netflix at 78 cents and Apple at 38 cents, is giving away the name and ticker free.
Watch the free presentation and get the ticker before July 13th
Mission Success in Record Time
Rocket Lab just delivered one of the more impressive operational feats in its history. As part of the U.S. Space Force's VICTUS HAZE mission, the company designed, built, and launched a spacecraft under tight deadlines, then executed a record-shattering responsive launch in just 16 hours and 42 minutes from notice to liftoff. The mission did not end there. Rocket Lab subsequently completed complex on-orbit rendezvous and proximity operations, proving its ability to track and inspect objects in space.
That capability matters enormously. Responsive launch and on-orbit inspection sit at the heart of what the Pentagon wants from commercial space partners, and no other company outside SpaceX has demonstrated it at this level. It is exactly the kind of execution that translates into future national security contracts, including work tied to the Golden Dome architecture and the Space-Based Interceptor program.
Morgan Stanley Sees a Path to $293
Despite the bearish price action and immense sell-off, analysts remain absolutely steadfast. On July 8, Morgan Stanley raised its bull-case price target for Rocket Lab to $293 from $185, while reiterating an Overweight rating and a $105 base-case target.
The bank's reasoning is straightforward: Rocket Lab is starting to look like a smaller SpaceX. The $8 billion acquisition of Iridium Communications, announced June 29, adds a global satellite network, L-band spectrum, and millions of recurring subscribers, continuing to transform Rocket Lab from a launch company into a vertically integrated space platform. As the analyst put it, the greatest value creation in the space economy comes not from launch alone, but from owning differentiated space-based infrastructure and monetizing recurring services.
Reaching $293 would require a clean, on-time Neutron debut, successful Iridium integration, and major defense awards converting into signed contracts. But even the $105 base case implies meaningful upside from current levels, and the consensus price target of $108.24 across 21 analysts sits over 31% above where the stock trades.
BioStem files Form 10 in push toward Nasdaq uplisting (Ad)
BioStem ($BSEM) has officially filed a Form 10, marking a significant milestone in its path toward becoming an SEC reporting company and pursuing a potential Nasdaq uplisting.
While the uplisting is not yet complete, this filing represents one of the most concrete steps the company has taken after more than a year of progress toward the goal.
Learn what the Form 10 filing means for BSEM investors
The Technical Line in the Sand
From a technical perspective, the picture is simpler. After a 45% drawdown, the big line in the sand for the bulls is the 200-day SMA, sitting around $76 per share. The stock has so far held above that level even through the worst of the selling. If it continues to defend that zone, a durable base could form, giving long-term buyers a defined-risk entry point. A decisive break below it, however, would put the broader uptrend that has been in place since early 2025 in genuine question. Until the stock reclaims higher levels, this remains a stabilization attempt rather than a confirmed reversal.
One notable caution for investors to note that could continue to weigh on the stock’s price action is insider selling. Insider selling has added to the negative sentiment, with CEO Peter Beck disclosing the sale of nearly 3 million shares over the past week. Insider sales after a massive multi-year run are not unusual, but the timing has not helped the tape.
August 6: The Next Big Catalyst
Q2 earnings are expected to arrive on August 6, and the report gives management the chance to reset the narrative. Investors should focus on four things. First, revenue was against the guided range of $225 million to $240 million, which came in well above consensus when issued. Second, any update on Neutron's debut timeline, the single most important variable in the Morgan Stanley bull case. Third, commentary on the Iridium deal, including the closing timeline and early integration planning. And fourth, backlog growth, which stood at a record $2.2 billion last quarter.
For long-term investors, the setup is compelling but conditional. The business is executing at the highest level in its history, the analyst community sees substantial upside, and the stock is down almost 45% from its peak. If the 200-day SMA holds and the August 6 report confirms the fundamental trajectory, this pullback may eventually be remembered as the opportunity it increasingly appears to be.
Read More
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Before SpaceX goes public, watch this tiny supplier closely (From Weiss Ratings)
- Micron's $250 Billion Bet Could Reshape the AI Memory Race
- I have a critical warning to share with you today (From Golden Portfolio)
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
- Broadcom's $30 Billion Apple Deal: This Chip Giant Is About More than Just AI
- IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave
Stay Ahead of the Market
The best investment opportunities don't wait. Get our research and stock ideas delivered straight to your smartphone—so you never miss a market-moving opportunity. Our text alerts ensure you see timely stock ideas and professional research reports instantly, whether you're in a meeting, commuting, or away from your desk.


